Siegfried Holding Ag · SIX:SFZN
Siegfried — Investor Presentation (September 2023)
27 slides from Siegfried's investor presentation, September 2023
Slide 1: Siegfried at a glance
Siegfried at a glance
Slide 2: About us
About us Siegfried at a glance
Slide 3: Siegfried at a glance – a globally leading CDMO
Siegfried at a glance – a globally leading CDMO PRODUCTION OF HEADQUARTERED IN PUBLICLY LISTED Active Pharmaceutical Ingredients and Finished Dosage Forms Zofingen (CH) since 1973 NUMBER OF SITES GLOBALLY EXPAND GLOBAL REVENUE 2022 (CHF) GROWTH SINCE 2010 11 6 x API, 5x FDF thereof 2 in Spain >1.2bn
Slide 4: Our offering along the value chain
Our offering along the value chain We offer integrated supply of APIs and finished products. Integration Drug Substances (DS) DS & DP Drug Products (DP) Drug Process Dosage Clinical Commercial Marketing discovery development Intermediates API formulation supplies production & distribution Bringing t
Slide 5: Our production network offers flexibility and integration
Our production network offers a unique combination of flexibility and integration for both, innovative an generic products Zofingen Switzerland 1 DS Development & Manufacturing Pennsville USA 2 DS Manufacturing 7 Hal Far Malta 3 DP Manufacturing 1 6 Irvine USA 4 8 DP Manufacturing 4 Nantong China 5
Slide 6: Our mission, vision, values
Our mission Our vision Our values Siegfried at a glance
Slide 7: >100 million patients served
Siegfried does matter to customers patients and society – every day, everywhere 10x Siegfried supplies approx. 200 >100 million A few 100 m doses FDA-approved APIs, thereby acting patients served by of Covid-19 vaccines were as a significant source to patients‘ Siegfried annually, based manufactured
Slide 8: Our mission: We do matter to customers, patients and society
Our mission: We do matter to customers, patients and society «With mastery of science and technology, we take the precious innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide» 8
Slide 9: Our vision: We aim for industry leadership
Our vision: We aim for industry leadership «Siegfried is the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space – because… …we are the strongest team running the most competitive network» 9
Slide 10: Our values: We strive for outstanding performance
Our values: We strive for outstanding performance Excellence «Our values and leadership principles are «We excel in everything we do» the basis to build the strongest team in the industry» Passion «We deeply care ybout what we do and how we do it» Integrity «We act responsibly, reliably, respectfull
Slide 11: Our leadership values are the basis to build the strongest team
Our leadership values are the basis to build the strongest team in the industry Foster Empower customer people intimacy Deliver quality Ensure and value performance Focus on Lead and customers develop people Foster innovation Drive business Excellence and excellence growth Passion Manage Lead and In
Slide 12: Our history
Our history Siegfried at a glance
Slide 13: Our history
Our history 1873 Pharmacist Samuel Benoni Siegfried founded a comapy with 12 employees as a supplier to pharmacies 1973 Quotation on the Swiss Stock Exchange (SWX) in Basel 1991 2005 Focus on custom Akquisition der development and Penick Corporation manufacturing in New Jersey (USA) 2001 2007 Buildi
Slide 14: Our history
Our history 2012 Acquisition of Alliance Medical Products (AMP) in 2021 Irvine (CA, USA) Acquisition of two pharmaceutical production sites from Novartis in Barberà del Vallès and El Masnou (ES) 2023 Acquisition of a 2014 majority stake in Acquisition of Hameln Pharma DiNAMIQS, a in Hameln (DE) Swis
Slide 15: Our management
Our managment Siegfried at a glance
Slide 16: Management – Board of Directors
Management – Board of Directors Dr. Andreas Casutt CHAIRMAN Dr. Martin Schmid Dr. Alexandra Brand Dr. Beat Walti Prof. Dr. Wolfram Carius Isabelle Welton Elodie Cingari 16
Slide 17: Management – Executive Committee
Management – Executive Committee Dr. Wolfgang Wienand Henrik Krüpper CHIEF EXECUTIVE OFFICER CHIEF OPERATING OFFICER DRUG SUBSTANCES Dr. Reto Suter Dr. Jürgen Roos CHIEF FINANCIAL OFFICER CHIEF SCIENTIFIC OFFICER Christian Dowdeswell Marianne Späne CHIEF CHIEF BUSINESS BUSINESS OFFICER OFFICER CHIEF
Slide 18: Our business model
Our business model Siegfried at a glance
Slide 19: Drug Substances and Drug Products overview
Overview Drug Substances APIs, intermediates Chemical controlled substances Chemical process procuction development Pharmaceutical Pharmaceutical development Solid dosage forms production services (including capsules for inhalation) Semi-solid dosage forms (ophthalmic ointments) Liquid dosage forms
Slide 20: Our financials
Our financials Siegfried at a glance
Slide 21: Net sales
Net sales Net sales split 2022 CHF million 2022 2021 Change Drug Substances 753.7 656.0 +14.9% Drug Products 475.8 446.4 +6.6% Total 1 229.5 1 102.4 +11.5% (+15.6% in LC) 38.7% 61.3% Drug Products Drug Substances 21
Slide 22: Business development
Business development Net sales (in million CHF) 1.229,5 1.102,4 845,1 794,3 833,5 2018 2019 2020 2021 2022 22
Slide 23: Business development – Share Price Development
Business development iL idl Share Price Development from January 1, 2018, to December 31, 2022 8 8 3 : af : - wae | rr 200 2018 a 2019 a 2020 aa 2021 a 2022 23 Siegfried
Slide 24: Sustainability
Sustainability Siegfried at a glance
Slide 25: We do not only think about tomorrow, but far beyond
We do not only think about tomorrow, but far beyond Siegfried started its Cross-functional Commitment: ESG journey years ago: ESG Governance Board Siegfried’s carbon › Code of Business Conduct sponsored by CEO and footprint to be reduced › Global Quality Policy supervised by BoD by 50% until 2030 ›
Slide 26: Our reporting & recognition
Our reporting & recognition 26
Slide 27: Contact us
CONTACT US Head Office Siegfried AG Untere Bruehlstrasse 4 4800 Zofingen Switzerland Tel. +41 62 746 11 11 info@siegfried.ch www.siegfried.ch 27
Siegfried Holding — Investor Presentation (September 2023) on 6ix